Introduction/Background* Endometrial cancer (EC) patients have a good prognosis at early stages, but for recurrent or metastatic EC the prognosis remains poor. EC treatments are related to known prognostic factors included in ESMO-ESGO-ESTRO risk classes classification, but they are not sufficient to predict outcomes or recurrence rate of early stages. To improve patient clinical management and allow personalized therapy a better characterization of risk classes in EC is needed. To fill this gap, we investigated EC immune escape processes, customized on the knowledge of maternal-fetal interface immune mechanisms, since the two processes share common pathways.

Methodology This has been addressed by the identification of potential shared immune-based signatures between maternal-fetal interface and EC, such as those linked to lectin-type oxidized LDL receptor 1 (LOX-1) and NALP3 inflammasome, in order to achieve a potential immune score implementation to better characterize EC risk classes. The immunohistochemical assessment of LOX-1 and NALP3 was performed on formalin-fixed paraffin-embedded (FFPE) endometrial tissues.

Result(s)* 41 patients divided in 3 groups were enrolled: healthy endometrial tissue, endometrial hyperplasia and EC. We detected an increased expression of LOX-1, by immunohistochemistry (IHC), within the endometrial carcinoma tissues, a lower expression in cases of hyperplasia, to arrive to an absent staining in the healthy endometrial tissue (* $p < 0.05$, *Kruskal-Wallis followed by Mann-Whitney test).

Abstract 501 Figure 1 Immunohistochemical staining on formalin-fixed paraffin-embedded samples of endometrial tissue showing expression of LOX-1 and NALP3 markers

0.05, *Kruskal-Wallis followed by Mann-Whitney test). This grading is inverted in NALP3, which expression appears to be lower in EC (* $p < 0.05$). A proportional relationship between LOX-1 and NALP3 expression was demonstrated ($p = 0.006$, Spearman test, confirmed through a linear regression test): increasing the expression of LOX-1, NALP3 decreases.

Conclusion* An increased LOX-1 and a decreased NALP3 expression seems be associated with EC progression. To identify patients at risk of developing EC from pre-cancerous lesions, by searching potential immune prognostic factors, such as LOX-1 and NALP3 on endometrial biopsy, could re-define the actual EC risk classes through a potential 'immune score' creation. Nevertheless, further studies are needed to define EC transcriptome immune-based signature. Furthermore, pathways detected by deciphering the immune changes linked to EC progression, could be potential target for immunotherapy.

Abstract 501 Table 1 Clinical and pathologic features of enrolled features

CHARACTERISTICS	Physiologic endometrium (n 7)	Endometrial hyperplasia (n 22)	Endometrial cancer (n 12)
Mean Age $\pm$ S.D.	58 $\pm$ 13 years	51.8 $\pm$ 10.4	50.7 $\pm$ 10.5
Mean BMI $\pm$ S.D.	26.5 $\pm$ 5.1 kg/m ²	26.8 $\pm$ 7.2	32 $\pm$ 9.1
Menopausal Status			
YES	5	10	9
NO	2	12	3
FIGO Stage			
IA	NA	NA	6
IB			6
Hysteroscopy with endometrial biopsy		11	
Total hysterectomy	7	11	
Radical Hysterectomy			
Type A			12
Lymphadenectomy			
Not performed			6
Pelvic	NA	NA	6
Para-Aortic			0
Grading			
1			4
2	NA	NA	4
3			4
EC Histology			
Endometrioid	NA	NA	12
Recurrences	NA	NA	0

506 DOES ANANDAMIDE PREVENT ENDOMETRIAL CANCER GROWTH THROUGH ANTI-PROLIFERATION OR MODULATION OF APOPTOSIS?

¹T Ayakannu*, ²A Taylor, ³J Konje. ¹Liverpool Women's Hospital, UK; ²University of Leicester, Department of Molecular and Cell Biology, UK; ³University of Leicester, Department of Health Sciences, UK

10.1136/ijgc-2021-ESGO.160

Introduction/Background* Previously, we and others have demonstrated that the N-acyl ethanolamine, anandamide, inhibits endometrial cancer (EC) cell growth in-vitro^{1,2}. The mechanism probably involves cellular apoptosis², through modulation of pro-apoptotic (BAX) and anti-apoptotic molecules (Bcl-2). Our aim here was to investigate the distribution patterns of these proteins and that of a cell proliferation marker in patients with and without EC.

Methodology Endometrial biopsies from patients with Type 1 (n=18), Type 2 EC (n=10) and normal atrophic endometria (n=6) were subjected to immunohistochemistry with commercial antibodies to BAX, Bcl-2 or Ki-67. Histomorphometric analyses of the glands and stroma were measured independently on 10 random fields from each sample using ImageScope software³. The mean $\pm$ SEM were calculated, and significance ($p < 0.05$) determined using ANOVA.

Result(s)* BAX protein was significantly higher in Type 1 ($p=0.004$) and Type 2 ($p=0.024$) EC compared to atrophic samples; both types showing higher levels in the glandular tissue; only Type 1 EC demonstrated significantly higher stromal staining. By contrast, Bcl-2 expression was significantly ($p=0.017$) lower only in Type 2 EC. Increased proliferation (Ki-67 staining) of both Type 1 ($p=0.003$) and Type 2 ($p<0.0001$) EC was observed. The BAX:Bcl-2 ratio was only significantly ($p<0.001$) higher in the Type 2 EC because of glandular expression. BAX expression ($r=0.615$; $p=0.0001$), and the BAX:Bcl-2 ratio ($r=0.507$; $p=0.003$) were directly related to proliferation whilst Bcl-2 expression was inversely related ($r=-0.544$; $p=0.0009$).

Conclusion* Since BAX (pro-apoptotic signal) was increased in both types of EC, whilst Bcl-2 (anti-apoptotic signal) was decreased, then increased apoptosis is present in EC tissue. The direct correlation between the BAX:Bcl-2 ratio (indicator of increased or decreased apoptosis) and cellular proliferation indicates that as the tumours grow, they also undergo significant apoptosis. Since these tissues have increased production of anandamide₄, then it is probable that anandamide is not stimulating cellular proliferation but is attempting to control tissue hyperplasia through increased apoptosis.

511 OBTURATIVE NERVE COMPLICATION IN LAPAROSCOPIC TREATMENT OF ENDOMETRIAL CANCER

E Milnerowicz-Nabzyk*, M Kalus, K Nowak, J Tomiczek-Szwiec, M Mrugała, A Machnicka-Rusek. *SPZOZ Opolskie Centrum Onkologii im. prof. Tadeusza Koszarowskiego, Opole, Poland*

10.1136/ijgc-2021-ESGO.161

Introduction/Background* Intraoperative, iatrogenic damage of peripheral nerves are rare but serious operative complication. Miss it or incorrect repair can get serious consequences for patient. During laparoscopic pelvic lymphadenectomy, specially when we remove metastases from obturator fossa, the risk of damage obturator nerve is considerable. Very important is correct intraoperative diagnosis of those complication and the knowledge of repair techics.

Methodology The aim of reconstruction of damaging obturator nerve is to restore the appropriate function. That's the motoric nerve responsible for adduction and walking. Subtile disfunction of a sensation are possible as well.

Result(s)* 54 years old women with clarocellular endometrial cancer with Massive infiltration of cervix, was admitted to Oncological Center for surgical treatment. She was previously hospitalized in Oncosurgery department due to isolating change in paraaortic lymphnodes. The enlarged nodous were removed. In H-P the suspicious of the endometrial cancer as primary focus were given. In CT and MRI examinations the selective pathology of lymphnodes of the left pelvic side were detected. The radical hysterectomy type B with selective lymphadenectomy of the left side were done. During dissection of obturative space the iatrogenic damage of the obturative nerve were detected. The preparation of whole obturative nerve were performed end to end anastomosis with 6.0 monofilament suture was made. The surgery were continued due to qualification. In postoperative observation the patient didn't claimed any mobile disfunction of

the left leg. In neurological examination discreet symptoms of disfunction could be observed, which subside in a few weeks.

Conclusion* Described case proves that laparoscopic technique has the benefits not only in minimally invasive treatment of endometrial cancer but in neural complications as well what could be much more difficult in traditional laparotomical route.

514 ENDOMETRIAL CANCER IN PRE-MENOPAUSAL WOMEN: CLINICAL AND PROGNOSTIC FACTORS ANALYSIS IN A TERTIARY CENTRE

R Bermejo Martínez*, MDLR Oliver, C Álvarez Conejo, G López González, B Gil Ibáñez, JM Seoane Ruiz, Á Tejerizo García. *University Hospital October 12, Madrid, Spain*

10.1136/ijgc-2021-ESGO.162

Introduction/Background* Management of endometrial cancer (EC) in pre-menopausal women represents nowadays a clinical challenge. The median age of diagnosis of EC is 65 years. Prevalence has increased in the last years in younger people related to increased risk factors. Around 20% of cases are diagnosed before menopause. EC typically presents with abnormal uterine bleeding. The diagnostic evaluation of premenopausal patients with this main clinical feature supposes an additional difficulty. The aim of our study is to evaluate the clinical and pathologic factors associated with EC in this group.

Methodology Retrospective unicentric study of 244 patients with EC diagnosed, treated and followed-up at *Hospital Universitario 12 de Octubre* (Madrid, Spain) between 2013 and 2020. Exclusion criteria were neoadjuvant chemotherapy or primary radiation as treatment. Menopausal status at diagnosis was used to classify patients into two groups.

Result(s)* A total of 244 patients were included, of which 45 (18.4%) were pre-menopausal and 199 (81.6%) were postmenopausal. **Demographic and pathologic characteristics of the two cohorts are described in table 1.**

Conclusion* In our institution, premenopausal status was associated with a lower parity record (1.1 ± 0.8 vs 2.15 ± 1.3 , $p=0.04$), lower prevalence of hypertension (13.0% vs 59.4%, $p=0.001$), higher rate of smokers (28.9% vs 14.9%, $p=0.039$) and endometrioid histology (97.8% vs 83.5%, $p=0.01$). Hysterectomy was performed in all cases, and only one premenopausal patient underwent ovarian preservation. A total of 39.1% and 38.0% of the patients had pelvic lymph node assessment in the premenopausal and postmenopausal groups, respectively ($p=0.4$) and paraaortic in 37.0% and 30.0% ($p=0.19$). There was no significant difference in stage distribution, grade differentiation, myometrial invasion or lymphovascular space invasion, between the two groups. The rate of administration of adjuvant chemotherapy was 15.6% in premenopausal and 13.8% in postmenopausal patients ($p=0.75$) and 28.9% and 37.9% ($p=0.26$) of adjuvant radiotherapy, respectively. According to these results, in our population, there was no significant difference in the favourable clinical prognostic factors in premenopausal women. The retrospective nature of the study and the small size of the cohort could justify these findings.